Do SGLT-2 inhibitors improve cardiovascular outcomes in patients with type 2 diabetes?

    loading  Checking for direct PDF access through Ovid

Abstract

EVIDENCE-BASED ANSWER

Yes. In patients with type 2 diabetes, treatment with sodium glucose cotransporter 2 (SGLT2) inhibitors lead to a 30% to 40% decreased risk of cardiovascular death and a 30% decreased risk death from any cause. They also lead to reductions in other major adverse cardiovascular outcomes including new-onset heart failure and hospitalization due to heart failure (SOR: A, meta-analyses of RCTs, heavily influenced by 1 RCT).

Related Topics

    loading  Loading Related Articles